Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.75 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.56 |
| ▸ | IGF2R | P11717 | 4/20 | 0.53 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.43 |
| ▸ | UMPS | P11172 | 3/20 | 0.42 |
| ▸ | ATIC | P31939 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14503325 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL14985153 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL18294135 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL10064521 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL19454793 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL23960812 | 1.00 | FBP1 (0.75) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL13857406 | 0.98 | FBP1 (0.72) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL29323929 | 0.98 | FBP1 (0.72) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL18710783 | 0.98 | FBP1 (0.72) | FBP1AMDHD2IGF2RP2RY2P2RY6 | |
| SCHEMBL29324521 | 0.98 | FBP1 (0.72) | FBP1AMDHD2IGF2RP2RY2P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024050815-A1 | USE OF HETEROAROMATIC RING COMPOUNDS IN NUCLEIC ACID TESTS | 深圳华大生命科学研究院 | 2024-03-14 | — | — | WO | disclosed |
| US-9782462-B2 | Modified polynucleotides for the production of proteins associated with human disease | MODERNATX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9504734-B2 | Modified polynucleotides for the production of nuclear proteins | MODERNATX, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160205924-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | MODERNATX, INC. | 2016-07-21 | — | — | US | disclosed |
| US-20160114011-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2016-04-28 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| US-9114113-B2 | Modified polynucleotides encoding citeD4 | MODERNA THERAPEUTICS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150064235-A1 | MODIFIED POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2015-03-05 | — | — | US | disclosed |
| US-20150064236-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2015-03-05 | — | — | US | disclosed |
| US-20150051268-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | MODERNATX, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20150050354-A1 | MODIFIED POLYNUCLEOTIDES FOR THE TREATMENT OF OTIC DISEASES AND CONDITIONS | MODERNATX, INC. | 2015-02-19 | — | — | US | disclosed |
| US-20150044277-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CASPASE 3 | MODERNA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20140186432-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CITED4 | MODERNA THERAPEUTICS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140155475-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING LIPASE A, LYSOSOMAL ACID, CHOLESTEROL ESTERASE PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051268-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | FBP1 2121/4885AMDHD2 206/4885IGF2R 2460/4885 |
| US-20150044277-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CASPASE 3 | CASP3, POLRMT, NSUN3 | FBP1 3993/4885AMDHD2 3146/4885IGF2R 1918/4885 |
| US-20140186432-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CITED4 | POLN, CXXC4, POLRMT | FBP1 3552/4885AMDHD2 3989/4885IGF2R 1834/4885 |
| US-20160114011-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | FBP1 3278/4885AMDHD2 3898/4885IGF2R 1528/4885 |
| US-20150050354-A1 | MODIFIED POLYNUCLEOTIDES FOR THE TREATMENT OF OTIC DISEASES AND CONDITIONS | OTC, POLRMT, POLN | FBP1 2229/4885AMDHD2 3560/4885IGF2R 1245/4885 |
| US-20150064235-A1 | MODIFIED POLYNUCLEOTIDES | POLRMT, POLN, MSH2 | FBP1 4274/4885AMDHD2 4655/4885IGF2R 870/4885 |
| US-20160205924-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | FBP1 2121/4885AMDHD2 206/4885IGF2R 2460/4885 |
| US-20150064236-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS | POLRMT, MSH2, POLN | FBP1 3279/4885AMDHD2 4125/4885IGF2R 882/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | FBP1 2766/4885AMDHD2 734/4885IGF2R 750/4885 |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | RNGTT, NSUN3, CPSF6 | FBP1 388/4885AMDHD2 1592/4885IGF2R 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.